ApprovalTrail

Company · Saint-Laurent, Quebec, Canada

Celgene Inc

Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.

Drug products (DIN)
4
0 authorized now
Natural health products
0
0 active licences
Medical device licences
0
0 active
Notices of Compliance
56

Drug products

Authorized products first.

NameDINStatus
ABECMA02516233Cancelled Pre Market
IDHIFA02485427Cancelled Post Market
IDHIFA02485435Cancelled Post Market
THALOMID02355213Cancelled Pre Market

Notices of Compliance

Newest first.

  • ZEPOSIADecember 20, 2023 · NOC 32394 · Supplement to a New Drug Submission (SNDS)
  • ABRAXANE FOR INJECTABLE SUSPENSIONAugust 17, 2023 · NOC 31432 · Supplement to a New Drug Submission (SNDS)
  • INREBICJuly 12, 2023 · NOC 31200 · Supplement to a New Drug Submission (SNDS)
  • POMALYSTJune 23, 2023 · NOC 31048 · Supplement to a New Drug Submission (SNDS)
  • IDHIFAJune 9, 2023 · NOC 30960 · Supplement to a New Drug Submission (SNDS)
  • REVLIMIDApril 2, 2023 · NOC 30621 · Supplement to a New Drug Submission (SNDS)
  • ISTODAXMarch 14, 2023 · NOC 30335 · Supplement to a New Drug Submission (SNDS)
  • INREBICDecember 13, 2022 · NOC 29735 · Supplement to a New Drug Submission (SNDS)
  • REBLOZYLNovember 21, 2022 · NOC 29512 · Supplement to a New Drug Submission (SNDS)
  • ABRAXANE FOR INJECTABLE SUSPENSIONNovember 2, 2022 · NOC 29367 · Supplement to a New Drug Submission (SNDS)
  • INREBICOctober 11, 2022 · NOC 29176 · Supplement to a New Drug Submission (SNDS)
  • INREBICSeptember 14, 2022 · NOC 28952 · Supplement to a New Drug Submission (SNDS)
  • REVLIMIDAugust 2, 2022 · NOC 28694 · Supplement to a New Drug Submission (SNDS)
  • VIDAZAJune 21, 2022 · NOC 28437 · Supplement to a New Drug Submission (SNDS)
  • BREYANZIMay 6, 2022 · NOC 28100 · New Drug Submission (NDS)
  • ZEPOSIAApril 8, 2022 · NOC 27939 · Supplement to a New Drug Submission (SNDS)
  • REBLOZYLNovember 3, 2021 · NOC 26991 · Supplement to a New Drug Submission (SNDS)
  • ZEPOSIAOctober 29, 2021 · NOC 26938 · Supplement to a New Drug Submission (SNDS)
  • INREBICSeptember 10, 2021 · NOC 26633 · Supplement to a New Drug Submission (SNDS)
  • REBLOZYLSeptember 8, 2021 · NOC 26618 · Supplement to a New Drug Submission (SNDS)
  • ABECMAMay 26, 2021 · NOC 25936 · New Drug Submission (NDS)
  • THALOMIDMarch 29, 2021 · NOC 25553 · Supplement to a New Drug Submission (SNDS)
  • REBLOZYLFebruary 11, 2021 · NOC 25187 · New Drug Submission (NDS)
  • POMALYSTFebruary 2, 2021 · NOC 25139 · Supplement to a New Drug Submission (SNDS)
  • ONUREGJanuary 5, 2021 · NOC 24927 · New Drug Submission (NDS)
  • IDHIFADecember 4, 2020 · NOC 24745 · Supplement to a New Drug Submission (SNDS)
  • VIDAZAOctober 15, 2020 · NOC 24441 · Supplement to a New Drug Submission (SNDS)
  • ZEPOSIAOctober 2, 2020 · NOC 24355 · New Drug Submission (NDS)
  • REBLOZYLSeptember 25, 2020 · NOC 24315 · New Drug Submission (NDS)
  • INREBICJuly 27, 2020 · NOC 23965 · New Drug Submission (NDS)
  • POMALYSTJuly 30, 2019 · NOC 22477 · Supplement to a New Drug Submission (SNDS)
  • ISTODAXJuly 26, 2019 · NOC 22454 · Supplement to a New Drug Submission (SNDS)
  • POMALYSTJuly 2, 2019 · NOC 22354 · Supplement to a New Drug Submission (SNDS)
  • IDHIFAFebruary 6, 2019 · NOC 21837 · New Drug Submission (NDS)
  • POMALYSTApril 11, 2017 · NOC 19240 · Supplement to a New Drug Submission (SNDS)
  • ISTODAXDecember 20, 2016 · NOC 18803 · Supplement to a New Drug Submission (SNDS)
  • REVLIMIDDecember 14, 2016 · NOC 18770 · Supplement to a New Drug Submission (SNDS)
  • THALOMIDSeptember 30, 2016 · NOC 18534 · Supplement to a New Drug Submission (SNDS)
  • ABRAXANEJanuary 18, 2016 · NOC 17695 · Supplement to a New Drug Submission (SNDS)
  • REVLIMIDOctober 16, 2015 · NOC 17538 · Supplement to a New Drug Submission (SNDS)
  • VIDAZAAugust 14, 2015 · NOC 17203 · Supplement to a New Drug Submission (SNDS)
  • OTEZLA; OTEZLA (27-COUNT STARTER PACK)June 10, 2015 · NOC 16986 · New Drug Submission (NDS)
  • REVLIMIDMay 4, 2015 · NOC 16861 · Supplement to a New Drug Submission (SNDS)
  • OTEZLA; OTEZLA (27-COUNT STARTER PACK)November 12, 2014 · NOC 16279 · New Drug Submission (NDS)
  • ABRAXANEJuly 16, 2014 · NOC 15966 · Supplement to a New Drug Submission (SNDS)
  • POMALYSTJanuary 20, 2014 · NOC 15139 · New Drug Submission (NDS)
  • ISTODAXOctober 16, 2013 · NOC 14814 · New Drug Submission (NDS)
  • ABRAXANEOctober 16, 2013 · NOC 14822 · Supplement to a New Drug Submission (SNDS)
  • REVLIMIDJune 6, 2013 · NOC 14446 · Supplement to a New Drug Submission (SNDS)
  • VIDAZAMay 2, 2012 · NOC 13243 · Supplement to a New Drug Submission (SNDS)
  • ABRAXANE FOR INJECTABLE SUSPENSIONMarch 26, 2012 · NOC 13145 · New Drug Submission (NDS)
  • REVLIMIDOctober 1, 2010 · NOC 11773 · Supplement to a New Drug Submission (SNDS)
  • THALOMIDAugust 4, 2010 · NOC 11645 · New Drug Submission (NDS)
  • VIDAZAOctober 23, 2009 · NOC 10715 · New Drug Submission (NDS)
  • REVLIMIDOctober 3, 2008 · NOC 9811 · Supplement to a New Drug Submission (SNDS)
  • REVLIMIDJanuary 17, 2008 · NOC 9303 · New Drug Submission (NDS)

Recalls and safety alerts that mention its products

Health Canada’s recall notices do not carry licence numbers, so these are matched by name. A notice may cover another product or only some lots: read it to see what it covers.